Search Results - "Dharan, Bharani"

Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial by Wong, Connie C, Baum, Jason, Silvestro, Angela, Beste, Michael T, Bharani-Dharan, Bharani, Xu, Siyan, Wang, Ying A, Wang, Xiaoshan, Prescott, Margaret F, Krajkovich, Lynne, Dugan, Margaret, Ridker, Paul M, Martin, Anne-Marie, Svensson, Eric C

“…In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), inhibition of the IL1β inflammatory pathway by canakinumab has been shown to…”
Get full text

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial by Baselga, José, Prof, Im, Seock-Ah, Prof, Iwata, Hiroji, MD, Cortés, Javier, MD, De Laurentiis, Michele, MD, Jiang, Zefei, Prof, Arteaga, Carlos L, Prof, Jonat, Walter, Prof, Clemons, Mark, Prof, Ito, Yoshinori, MD, Awada, Ahmad, Prof, Chia, Stephen, MD, Jagiełło-Gruszfeld, Agnieszka, MD, Pistilli, Barbara, MD, Tseng, Ling-Ming, MD, Hurvitz, Sara, MD, Masuda, Norikazu, MD, Takahashi, Masato, MD, Vuylsteke, Peter, MD, Hachemi, Soulef, PhD, Dharan, Bharani, MS, Di Tomaso, Emmanuelle, PhD, Urban, Patrick, MD, Massacesi, Cristian, MD, Campone, Mario, Prof

“…Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast…”
Get full text

Port Site Metastases of Carcinoma Endometrium: Case Report and Literature Review by Shanmugam, S. Subbiah, Bharani dharan, Aravind, S.

“…Introduction Carcinoma endometrium with port site metastases usually have poor survival, we present a case of carcinoma endometrium with port site metastases…”
Get full text

Development of Essential Oil Delivery Systems by ‘Click Chemistry’ Methods: Possible Ways to Manage Duchenne Muscular Dystrophy by Kaspute, Greta, Arunagiri, Bharani Dharan, Alexander, Rakshana, Ramanavicius, Arunas, Samukaite-Bubniene, Urte

“…Recently, rare diseases have received attention due to the need for improvement in diagnosed patients’ and their families’ lives. Duchenne muscular dystrophy…”
Get full text

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design by Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit

“…The PI3K-AKT-mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective…”
Get full text

Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment by Iwata, Hiroji, Baselga, José, Campone, Mario, Arteaga, Carlos L., Cortes, Javier, Jonat, Walter, De Laurentiis, Michelino, Ciruelos, Eva, Janni, Wolfgang, Bachelot, Thomas, Lonning, Per Eystein, Ma, Cynthia, O'Regan, Ruth, Di Tomaso, Emmanuelle, Bharani-Dharan, Bharani, Duval, Vincent, Lau, Helen, Germa, Caroline, Urban, Patrick, Di Leo, Angelo

“…Abstract only TPS650^ Background: The PI3K/Akt/mTOR pathway is commonly dysregulated in BC and linked to resistance to endocrine therapy, including AIs…”
Get full text

Monitoring overall survival in pivotal trials in indolent cancers by Fleming, Thomas R, Hampson, Lisa V, Bharani-Dharan, Bharani, Bretz, Frank, Chakravartty, Arunava, Coroller, Thibaud, Koukouli, Evanthia, Wittes, Janet, Yateman, Nigel, Zuber, Emmanuel

“…Indolent cancers are characterized by long overall survival (OS) times. Therefore, powering a clinical trial to provide definitive assessment of the effects of…”
Get full text

Isovalent Doping of Cu2+ Induced Elastic Strain on Cobalt Spinel Oxides for Enhancing Room Temperature Thermoelectric Application by Sethuraman, Bharani Dharan, Veluswamy, Pandiyarasan, Ikeda, Hiroya, Mohandos, Sivakami

Get full text

Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions by Van Lancker, Kelly, Tarima, Sergey, Bartlett, Jonathan, Bauer, Madeline, Bharani-Dharan, Bharani, Bretz, Frank, Flournoy, Nancy, Michiels, Hege, Parra, Camila Olarte, Rosenberger, James L, Cro, Suzie

“…The COVID-19 pandemic continues to affect the conduct of clinical trials globally. Complications may arise from pandemic-related operational challenges such as…”
Get full text

The spinel-based pliable thermoelectric device for room temperature application by Chandrasekar, Lakshmi Prabha, Subramani, Manikandan, Sethuraman, Bharani Dharan, Ikeda, Hiroya, Mohandos, Sivakami, Veluswamy, Pandiyarasan

“…Copper aluminate is a p-type semiconductor material with moderate thermoelectric behavior. In contrast, for the first-time electron-enriched cobalt was…”
Get full text

Green synthesised ZnO nanoparticles from Plectranthus amboinicus plant extract: removal of Safranin- O and Malachite green dyes & anti-bacterial activity by Chandrasekar, Lakshmi Prabha, Sethuraman, Bharani Dharan, Subramani, Manikandan, Mohandos, Sivakami

“…The synthesis of Zinc oxide nanoparticles using a plant-mediated approach is presented in this paper. The nanoparticles were successfully synthesised using the…”
Get full text

Trachyspermum ammi Mediated Green Synthesis of NiO Nanoparticles: Dual Role in Photocatalytic Degradation and Anti-bacterial Efficacy by Sethuraman, Bharani Dharan, Chandrasekar, Lakshmi Prabha, Subramani, Manikandan, Mohandos, Sivakami

Get full text

Evolution of microorganisms in thermophilic dry anaerobic digestion by Hemusaiprakashreddy, D, Dharan, Bharani

“…[...]in order to acquire more detailed information in respect of this biomass, other parameters have also been used in the characterization of the…”
Get full text

Renewable Methane from Anarobic Diaestion of Biomass by Zaheer, Mohammed, Dharan, Bharani

“…Abstract Anaerobic assimilation could be a prepare by which microorganisms break down biodegradable material within the nonattendance of oxygen. Introduction…”
Get full text

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial by Di Leo, Angelo, Johnston, Stephen, Lee, Keun Seok, Ciruelos, Eva, Lønning, Per E, Janni, Wolfgang, O'Regan, Ruth, Mouret-Reynier, Marie-Ange, Kalev, Dimitar, Egle, Daniel, Csőszi, Tibor, Bordonaro, Roberto, Decker, Thomas, Tjan-Heijnen, Vivianne C G, Blau, Sibel, Schirone, Alessio, Weber, Denis, El-Hashimy, Mona, Dharan, Bharani, Sellami, Dalila, Bachelot, Thomas

“…Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit…”
Get full text

New Thermoelectric Material and Devices: Naphthol[1,3]oxazine and the Performance Compared with Bismuth Telluride by Subramani, Manikandan, Mohandos, Sivakami, Ikeda, Hiroya, Chandrasekar, Lakshmi Prabha, Sethuraman, BharaniDharan, Veluswamy, Pandiyarasan, Hemkumar, K.

“…Herein, we have developed a state-of-the-art approach toward an organic thermoelectric (OTE) device by synthesizing oxazine monomers…”
Get full text

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial by Tan, Daniel S W, Felip, Enriqueta, de Castro, Gilberto, Solomon, Benjamin J, Greystoke, Alastair, Cho, Byoung Chul, Cobo, Manuel, Kim, Tae Min, Ganguly, Sandip, Carcereny, Enric, Paz-Ares, Luis, Bennouna, Jaafar, Garassino, Marina Chiara, Schenker, Michael, Kim, Sang-We, Brase, Jan C, Bury-Maynard, Denise, Passos, Vanessa Q, Deudon, Stéphanie, Dharan, Bharani, Song, Yuanbo, Caparica, Rafael, Johnson, Bruce E

“…The addition of checkpoint inhibitors to first-line treatment has prolonged survival of patients with non-small-cell lung cancer (NSCLC), but prognosis remains…”
Get full text

Energy Efficient Next-Gen of Virtualization for Cloud-native Applications in Modern Data Centres by Dharan G., Bharani, Jayalakshmi, S.

“…In the new software-driven world this is the need of the hour to achieve success by accelerating development, delivery of applications and services rapidly…”
Get full text

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial by Paz-Ares, Luis, Goto, Yasushi, Wan-Teck Lim, Darren, Halmos, Balazs, Chul Cho, Byoung, Cobo, Manuel, Luis González Larriba, José, Zhou, Caicun, Demedts, Ingel, Atmaca, Akin, Baka, Sofia, Mookerjee, Bijoyesh, Portella, Socorro, Zhu, Zewen, Wu, Jincheng, Demanse, David, Dharan, Bharani, Reck, Martin

“…•Patients with non-small cell lung cancer (NSCLC) have limited treatment options.•Canakinumab is approved for some autoinflammatory conditions.•Canakinumab…”
Get full text

Abstract A050: PIK3CA mutation status in tumor tissue and ctDNA as a biomarker for PFS in patients with HR+, HER2- ABC treated with buparlisib or placebo plus fulvestrant: results from the BELLE-2 and BELLE-3 randomized studies by Baselga, José, Sellami, Dalila, El-Hashimy, Mona, Dharan, Bharani, Wang, Amanda, Scheuer, Nicolas, Sankaran, Banu, Di Leo, Angelo

“…Abstract Background: PIK3CA mutation status is a potential biomarker for treatment response to buparlisib (BUP; pan-phosphatidylinositol 3-kinase [PI3K]…”
Get full text